Glycine Treatment of Prodromal Symptoms

This study has been completed.
Stanley Medical Research Institute
Information provided by (Responsible Party):
Yale University Identifier:
First received: December 20, 2005
Last updated: March 28, 2012
Last verified: March 2012
This is an open label trial of the NMDA agonist glycine used alone for symptoms that appear to be prodromal for schizophrenia in adolescents and young adults.

Condition Intervention Phase
Drug: glycine
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Glycine Treatment of Prodromal Symptoms

Resource links provided by NLM:

Further study details as provided by Yale University:

Primary Outcome Measures:
  • Scale Of Prodromal Symptoms total score [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]

Enrollment: 10
Study Start Date: July 2002
Study Completion Date: November 2004
Primary Completion Date: November 2004 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1 Drug: glycine
0.8 g/kg/day


Ages Eligible for Study:   14 Years to 35 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • age 14-35
  • meets SIPS criteria for psychosis prodrome

Exclusion Criteria:

  • current antipsychotic medication
  • more than 4 weeks of antipsychotic medication lifetime
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00268749

Sponsors and Collaborators
Yale University
Stanley Medical Research Institute
Principal Investigator: Scott W Woods, MD Yale University
  More Information

No publications provided by Yale University

Additional publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Yale University Identifier: NCT00268749     History of Changes
Other Study ID Numbers: 02T-175 
Study First Received: December 20, 2005
Last Updated: March 28, 2012
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Prodromal Symptoms
Signs and Symptoms
Glycine Agents
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Pharmacologic Actions
Physiological Effects of Drugs processed this record on February 09, 2016